A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia

OBJECTIVE: Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL). However, this combination is unavailable in Japan because rituximab is not approved for CLL. We investigated the efficacy and safety...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Jpn J Clin Oncol
Autors principals: Izutsu, Koji, Kinoshita, Tomohiro, Takizawa, Jun, Fukuhara, Suguru, Yamamoto, Go, Ohashi, Yasuo, Suzumiya, Junji, Tobinai, Kensei
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7937417/
https://ncbi.nlm.nih.gov/pubmed/33244584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyaa215
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars